"Dec. 11, 2012 -- The diabetes and obesity epidemics may be fueling a dramatic rise in the number of people with vision problems, a new study suggests.
Rates of vision problems that can't be treated with glasses or contact lenses, know"...
ILEVRO (nepafenac ophthalmic suspension), 0.3% is indicated for the treatment of pain and inflammation associated with cataract surgery.
DOSAGE AND ADMINISTRATION
One drop of ILEVRO (nepafenac ophthalmic suspension), 0.3% should be applied to the affected eye one-time-daily beginning 1 day prior to cataract surgery, continued on the day of surgery and through the first 2 weeks of the postoperative period. An additional drop should be administered 30 to 120 minutes prior to surgery.
Use With Other Topical Ophthalmic Medications
ILEVRO (nepafenac ophthalmic suspension), 0.3% may be administered in conjunction with other topical ophthalmic medications such as beta-blockers, carbonic anhydrase inhibitors, alpha-agonists, cycloplegics, and mydriatics.
If more than one topical ophthalmic medication is being used, the medicines must be administered at least 5 minutes apart.
Dosage Forms And Strengths
Sterile Ophthalmic Suspension 0.3%
1.7 mL in a 4 mL bottle
3 mL in a 4 mL bottle
Storage And Handling
ILEVRO (nepafenac ophthalmic suspension), 0.3% is supplied in a white, oval, low density polyethylene DROP-TAINER® dispenser with a natural low density polyethylene dispensing plug and gray polypropylene cap presented in an overwrap (1.7mL fill only). Tamper evidence is provided with a shrink band around the closure and neck area of the package.
1.7 mL in 4 mL bottle NDC 0065-1750-07
3mL in 4 mL bottle NDC 0065-1750-14
Store at 2 - 25°C (36 - 77°F).
Protect from light.
Alcon Laboratories, Inc. Fort Worth, Texas 76134 USA. Rev: Feb 2014This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 12/14/2015
Additional Ilevro Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.